Key Highlights
- BTIG upgraded Tempus AI’s price target to $80 from $70 while reaffirming its Buy recommendation, driving shares up 6.9% to $66.21
- Positive Phase 3 trial data from Merck and Moderna’s personalized mRNA cancer treatment, which relies on Personalis’ sequencing technology, boosted investor sentiment
- TEM’s $1.5 billion Personalis acquisition announced last month now directly ties the company to breakthrough cancer therapy developments
- Second quarter results exceeded projections: adjusted loss per share of -$0.04 versus analyst estimates of -$0.14, with revenues reaching $382.49 million, marking 21.6% annual growth
- Wall Street maintains a Hold consensus with 17 analysts covering the stock: nine Buy recommendations, six Hold, two Sell, and an average target of $65.69
Shares of Tempus AI (TEM) advanced 6.9% to reach $66.21 during Thursday’s trading session after BTIG Research increased its price objective from $70 to $80 while maintaining its Buy stance. Trading activity was robust, with more than 4.5 million shares exchanged by midday.
Following a $61.25 close in the previous session, Thursday’s rally represented one of TEM’s most significant single-day advances in recent trading periods.
The upward movement stemmed from multiple factors beyond the analyst upgrade. Market participants are drawing connections between a breakthrough clinical trial announcement and Tempus AI’s upcoming $1.5 billion Personalis acquisition.
Merck and Moderna unveiled Phase 3 data on Wednesday for intismeran autogene, a personalized mRNA cancer vaccine administered alongside Keytruda. The INTerpath-001 study demonstrated that the combination therapy significantly enhanced recurrence-free survival among melanoma patients following surgical resection.
This marked the first successful Phase 3 outcome for a customized mRNA-based oncology treatment.
Moderna relies on Personalis’ sequencing infrastructure to examine tumor specimens and pinpoint specific neoantigens required for each patient’s individualized treatment. This connection directly implicates Tempus AI.
Before announcing the acquisition, Tempus AI had established a partnership with Personalis focused on commercializing minimal residual disease testing solutions. The acquisition agreement valued at $1.5 billion was unveiled last month.
Financial Performance Exceeds Forecasts
Tempus AI released its latest quarterly financial report on July 30. The firm recorded an adjusted loss of $0.04 per share, surpassing the Street’s expectation of -$0.14 by $0.10.
Quarterly revenue totaled $382.49 million, exceeding analyst projections of $379.69 million. This figure reflected year-over-year expansion of 21.6%.
During the comparable period last year, the company recorded a loss of $0.22 per share. Currently, the business operates with a negative net margin of 17.77% and negative return on equity of 50.28%.
The analyst community projects a full-year adjusted loss of $1.38 per share for Tempus AI.
Wall Street Sentiment
Besides BTIG’s bullish stance, Wall Street analysts display varied opinions on TEM. Piper Sandler reduced its price objective from $58 to $56 on August 4, maintaining a neutral outlook. Guggenheim elevated its target to $65 with a Buy rating in July.
Wolfe Research initiated coverage in June with a peer perform designation. Weiss Ratings adjusted the stock from sell (e+) to sell (d-) in August.
Among all covering analysts, nine recommend buying TEM, six suggest holding, and two advise selling. The overall consensus stands at Hold, with an average price target of $65.69.
Corporate insiders have been actively selling shares. CFO James Rogers disposed of $634,095 worth of stock in June. CEO Ryan Fukushima sold $1.91 million worth in July. During the past 90 days, company insiders collectively sold $33.26 million in stock.
At the current price of $66.21, TEM is positioned above both its 50-day moving average of $52.10 and its 200-day moving average of $51.16.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
